A new trading day began on Tuesday, with Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) stock price up 4.86% from the previous day of trading, before settling in for the closing price of $7.82. AMLX’s price has ranged from $1.86 to $8.72 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -78.71% over the last five years. Meanwhile, its annual earnings per share averaged 59.74%. With a float of $66.45 million, this company’s outstanding shares have now reached $89.16 million.
The firm has a total of 123 workers. Let’s measure their productivity. In terms of profitability, gross margin is 545.78%, operating margin of 79106.43%, and the pretax margin is 75596.39%.
Amylyx Pharmaceuticals Inc (AMLX) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Amylyx Pharmaceuticals Inc is 25.47%, while institutional ownership is 80.05%. The most recent insider transaction that took place on Aug 12 ’25, was worth 234,600. Before that another transaction happened on Mar 31 ’25, when Company’s Chief Financial Officer sold 10,896 for $3.47, making the entire transaction worth $37,806. This insider now owns 290,988 shares in total.
Amylyx Pharmaceuticals Inc (AMLX) Earnings and Forecasts
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -1.07 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.45 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 59.74% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 30.07% during the next five years compared to -78.71% drop over the previous five years of trading.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Trading Performance Indicators
Here are Amylyx Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 8.72.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.50, a number that is poised to hit -0.46 in the next quarter and is forecasted to reach -1.46 in one year’s time.
Technical Analysis of Amylyx Pharmaceuticals Inc (AMLX)
Analysing the last 5-days average volume posted by the [Amylyx Pharmaceuticals Inc, AMLX], we can find that recorded value of 0.85 million was lower than the volume posted last year of 1.11 million. As of the previous 9 days, the stock’s Stochastic %D was 49.24%.
During the past 100 days, Amylyx Pharmaceuticals Inc’s (AMLX) raw stochastic average was set at 90.73%, which indicates a significant increase from 70.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.38 in the past 14 days, which was lower than the 0.40 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.89, while its 200-day Moving Average is $4.96. Now, the first resistance to watch is $8.40. This is followed by the second major resistance level at $8.60. The third major resistance level sits at $8.89. If the price goes on to break the first support level at $7.91, it is likely to go to the next support level at $7.62. Should the price break the second support level, the third support level stands at $7.42.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Key Stats
With a market capitalization of 731.17 million, the company has a total of 89,167K Shares Outstanding. Currently, annual sales are 87,370 K while annual income is -301,740 K. The company’s previous quarter sales were 0 K while its latest quarter income was -41,440 K.
